Presentation
Corporate Presentation: 43rd Annual J.P. Morgan Healthcare Conference / Top Line Data Update, Presented January 13, 2025
News
-
Sling Therapeutics Presents Preclinical Data Demonstrating Linsitinib Decreases Immune Response in Mouse Model of Thyroid Eye Disease at IMMUNOLOGY2023™
– Data demonstrate significant improvements in clinically relevant endpoints including reduced inflammation of fat and muscle behind the eye – – Company evaluating linsitinib in global Phase 2b LIDS clinical trial for treatment of active, moderate to severe thyroid eye disease – Ann Arbor, MI, May 15, 2023 — Sling Therapeutics, Inc., a biopharmaceutical company…
-
Sling Therapeutics Announces Appointment of Jeffrey Kent, M.D., FACG, FACP, as Chief Medical Officer
– Dr. Kent brings greater than two decades of global industry experience to leadership team – – Appointment supports the global Phase 2b LIDS clinical trial for thyroid eye disease (TED) – Ann Arbor, MI, January 25, 2023 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for…
-
Sling Therapeutics Initiates Enrollment in Phase 2b LIDS Clinical Trial Evaluating Linsitinib in Thyroid Eye Disease
– First oral IGF-1R inhibitor to enter late-stage clinical trials for thyroid eye disease – – Global study being conducted in the U.S., Canada, UK, and Europe – Ann Arbor, MI, July 25, 2022 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid…
-
Sling Therapeutics Appoints Faheem Hasnain as Chairman of the Board of Directors
– Accomplished life sciences executive brings nearly four decades of experience in pharmaceutical and biotechnology drug development and business operations – Ann Arbor, MI, June 27, 2022 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the appointment…
-
Sling Therapeutics Launches with $35M Series A Financing to Develop Oral Small Molecule for Thyroid Eye Disease
– Company receives FDA IND clearance for linsitinib and prepares to initiate Phase 2b clinical trial – Ann Arbor, MI, June 13, 2022 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the official launch of the company…